IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
Life review of elderly depression
Development and application of ATR-FTIR spectroscopy for mixture homogeneity in pharmaceutical application
The Increasing Damage in Tubular Cell of Infant Mice’s Kidneys from Carbofuran Exposure during its Mothers’ Lactation Period
Trend of transsexualism problem and its implications towards muslim community in Malaysia
Development and validation of RP-HPLC method for the estimation of pidotimod in tablet dosage form
Evaluation of neurotoxicity of the ethanolic bark extract of Holarrhena pubescens Wall. ex G.Don in mice
Design, synthesis and evaluation of 2-aminobenzimidazole derivatives: strong candidate for PPAR gamma agonists.
Prediction of Heart Disease Using Feature Selection and Random Forest Ensemble Method
Strategies for Antiviral Drugs from Plants by Targeting the Hemagglutinin, Neuraminidase and other receptors of Influenza A virus
The impact of human resource and quality management in health care: A Review
12345678910...
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
A preclinical study on targeting glucose homeostasis using therapeutic intervention of ZnO nanoparticles

Author: DR. RAUT, DR. BISWADEEP DAS, DR. TANIA PAUL, DR.GAURI KULKARNI
Abstract: Myriads of research work is undertaken on Zinc oxide Nanoparticles (ZnO) but avenues for finding alternate therapy in Hyperglycemic is always open. Present study was put forth to determine the antihyperglycemic activity of 50 nm ZnO on Streptozotocin (STZ) induced Diabetic rats. To determine the interplay of oral hyperglycemic agents in controlling hyperglycemic activity when co administered with ZnO was the primary aim of the study. It was successfully achieved when ZnO and Glipizide was administered singly and in combination for 28 Days orally to diabetic rats. Streptozotocin induced diabetes causes oxidative stress in rats which is also evident in humans due to impairment of insulin release and concomitant rise in glucose. Therefore, attempts are made to reduce these free radical damage by use of ZnO. The microartchitecture of pancreas, liver and kidney which was disturbed in Diabetic rats were restored to near normal by the present intervention of ZnO singly and in combination with Glipizide- a sulphonylurea derivative. Hence, it can be concluded that ZnO can be used in future for managing metabolic disorders like Diabetes and Obesity as a therapy or as a carrier to accommodate oral hyperglycemic agent for easy drug delivery and bioavailability.
Keyword: Zinc Oxide Nanoparticles, Streptozotocin, Glipizide, Antioxidant, Histopathology
DOI: https://doi.org/10.31838/ijpr/2020.12.03.200
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free